Stay Connected

Stay informed about ALUNBRIG® (brigatinib)—sign up to be notified about product and news updates.

Required fields*

Please enter your first name.
Please enter your last name.
Please enter your email.
Please enter your specialty.


By clicking Sign Up, you agree to receive product and disease-state information from Takeda, its affiliates, service providers, and co-promotion partners.

Learn about Takeda’s Privacy Policy by clicking the link below.

By submitting this form, you agree to Takeda’s Terms of Use and Privacy Policy.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue >
Close

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel
Close